Patent application number | Description | Published |
20080226618 | HYDANTOIN DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS - This invention relates to compounds of the Formula (I), | 09-18-2008 |
20090170875 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS - This invention relates to compounds of the Formula (I): | 07-02-2009 |
20100179141 | NOVEL JNK INHIBITORS - Disclosed are compounds of the formula (I) wherein X is N or CH, and Y is N or CR | 07-15-2010 |
20100298314 | NOVEL JNK INHIBITORS - Disclosed are substituted imidazo[1,2-a]pyridines, imidazo[1,2-a]pyrazines, imidazo[1,2-c]pyrimidines and imidazo[1,2-d]triazines compounds of the formula: (1.0) Also disclosed are methods for treating JNK1 and ERK mediated diseases using the compounds of formula 1.0. | 11-25-2010 |
20110123435 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY - The present invention relates to compounds of Formula (I), below, (wherein X, R1, R2, R3, p, E, ring A, and ring B are as defined herein). The present invention also relates to compositions (including pharmaceutically acceptable compositions) comprising these compounds, alone and in combination with one or more additional therapeutic agents, and to methods for their use in inhibiting KSP kinesin activity, and for treating cellular proliferative diseases or disorders associated with KSP kinesin activity. Formula I | 05-26-2011 |
20110150757 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY - The present invention relates to compounds of Formula (I), below, (wherein R1, R2, R3, R27, R28, R29, p, E, ring A, and ring B are as defined herein). The present invention also relates to compositions (including pharmaceutically acceptable compositions) comprising these compounds, alone and in combination with one or more additional therapeutic agents, and to methods for their use in inhibiting KSP kinesin activity, and for treating cellular proliferative diseases or disorders associated with KSP kinesin activity. | 06-23-2011 |
20110171172 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY - The present invention relates to compounds of Formula (I), below, (wherein R | 07-14-2011 |
20110212078 | SYNTHESIS AND USE OF HETEROCYCLIC ANTIBACTERIAL AGENTS - This invention relates to compounds of the following Formula (I); or a pharmaceutically acceptable salt, solvate, ester or isomer thereof, which is useful for the treatment of diseases or conditions mediated by LpxC. | 09-01-2011 |
20120322791 | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS - The present invention provides Pyrazolopyrimidine Compounds of Formula (I): | 12-20-2012 |
20130096084 | NOVEL HETEROCYCLIC COMPOUNDS AS ERK INHBITORS - The present invention provides a compound of the Formula I: (Formular I should be inserted here) or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R, R1, R2 and R3 are as defined herein. The compounds are ERK inhibitors. Also disclosed are pharmaceutical compositions comprising the above compounds and methods of treating cancer using the same. | 04-18-2013 |
20130150362 | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS - The present invention relates to certain pyrazolo[1,5-a]pyrimidine compounds of Formula (I) as inhibitors of mammalian Target Of Rapamycin (mTOR) kinase, which is also known as FRAP, RAFT, RAPT or SEP. The compounds may be used in the treatment of cancer and other disorders where mTOR is deregulated. The present invention further provides pharmaceutical compositions comprising the pyrazolo[1,5-a]pyrimidine compounds. | 06-13-2013 |